Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT314 + pumitamig + chemotherapy in metastatic colorectal cancer
2025-521768-36-00Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised trial of GEN1059 and pumitamig in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, TEAEs and TRAEs and 4 more. Planned start Oct 2025; status: authorised.
02
Drugs
GEN1059pumitamig
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-521768-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521768-36-00.